Silica micro/nanospheres for theranostics: from bimodal MRI and fluorescent imaging probes to cancer therapy

• Shanka Walia and
• Amitabha Acharya

Beilstein J. Nanotechnol. 2015, 6, 546–558, doi:10.3762/bjnano.6.57

• synthesis was enhanced by using Y(NO3)3·6H2O and Eu2O3 as reactants, CTAB as surfactant and TEOS as alkyl silicate. Finally, the anticancer drug doxyrubicin (DOX) was loaded into the prepared NPs. Characterization of mesoporous silica NPs (MSN), YVO4:Eu3+ NPs and YVO4-MSNs were done by XRD, FTIR, TEM and

Release behaviour and toxicity evaluation of levodopa from carboxylated single-walled carbon nanotubes

• Julia M. Tan,
• Jhi Biau Foo,
• Sharida Fakurazi and
• Mohd Zobir Hussein

Beilstein J. Nanotechnol. 2015, 6, 243–253, doi:10.3762/bjnano.6.23

• (anticancer drug) onto the epidermal growth factor functionalized SWCNT [23]. Release behaviour of LD In this study, the release profiles for LD from SWCNT–COOH at PBS pH values of 7.4 and 4.8 were investigated and shown in Figure 5. Both of the release curves show a fast release in the early stage, followed

Anticancer efficacy of a supramolecular complex of a 2-diethylaminoethyl–dextran–MMA graft copolymer and paclitaxel used as an artificial enzyme

• Yasuhiko Onishi,
• Yuki Eshita,
• Rui-Cheng Ji,
• Masayasu Onishi,
• Takashi Kobayashi,
• Masaaki Mizuno,
• Jun Yoshida and
• Naoji Kubota

Beilstein J. Nanotechnol. 2014, 5, 2293–2307, doi:10.3762/bjnano.5.238

• modulation, was developed as a new type of anticancer drug. However, even if a patient is prescribed an anticancer agent, a cancer cell will soon change an antidrug gene, thereby increasing the power of multi-drug resistance (MDR) [10]. It can be imagined that the development of fatal MDR by a cancer cell to

Near-infrared dye loaded polymeric nanoparticles for cancer imaging and therapy and cellular response after laser-induced heating

• Tingjun Lei,
• Alicia Fernandez-Fernandez,
• Romila Manchanda,
• Yen-Chih Huang and
• Anthony J. McGoron

Beilstein J. Nanotechnol. 2014, 5, 313–322, doi:10.3762/bjnano.5.35

• often been correlated to a poor therapeutic outcome, since HIF-1 could circumvent the anticancer drug effect by protecting cells from drug-induced apoptosis [12][13][14]. Moreover, tumor angiogenesis occurs partly by activating the expression of VEGF, which is partially regulated by HIF-1 [15][16][17

Extracellular biosynthesis of gadolinium oxide (Gd₂O₃) nanoparticles, their biodistribution and bioconjugation with the chemically modified anticancer drug taxol

• Shadab Ali Khan,
• Sanjay Gambhir and
• Absar Ahmad

Beilstein J. Nanotechnol. 2014, 5, 249–257, doi:10.3762/bjnano.5.27

• were bioconjugated with the chemically modified anticancer drug taxol with the aim of characterizing the role of this bioconjugate in the treatment of cancer. The biosynthesized Gd2O3 nanoparticles were characterized by UV–vis spectroscopy, transmission electron microscopy (TEM), X-ray diffraction (XRD

• simple biological protocol for the synthesis of gadolinium oxide nanoparticles, studied their biodistribution, and bioconjugated these nanoparticles with the chemically modified anticancer drug taxol. This particular bioconjugation may result in an enhancement of the hydrophilicity of taxol and may

Magnetic-Fe/Fe₃O₄-nanoparticle-bound SN38 as carboxylesterase-cleavable prodrug for the delivery to tumors within monocytes/macrophages

• Hongwang Wang,
• Tej B. Shrestha,
• Matthew T. Basel,
• Raj K. Dani,
• Gwi-Moon Seo,
• Sivasai Balivada,
• Marla M. Pyle,
• Heidy Prock,
• Olga B. Koper,
• Prem S. Thapa,
• David Moore,
• Ping Li,
• Viktor Chikan,
• Deryl L. Troyer and
• Stefan H. Bossmann

Beilstein J. Nanotechnol. 2012, 3, 444–455, doi:10.3762/bjnano.3.51

• not been used as an anticancer drug directly in humans due to its inherent poor solubility in any pharmaceutically acceptable media (solubility in water <5 µg/mL). To overcome this disadvantage of SN38, two major basic strategies have been developed. The first strategy is to directly introduce